This article explores how Touchlight’s enzymatically amplified linear dbDNA™ technology overcomes the limitations of traditional plasmid-based methods in lentiviral vector (LVV) manufacturing. By optimizing vector design and transfection conditions, the study demonstrates that dbDNA™ can achieve high LVV titres comparable to plasmid-based systems, enabling faster and more scalable GMP-grade production.

What this article covers:

• How dbDNA™ technology significantly reduces production time and cost compared to plasmid-based methods.
• Understand the specific optimizations that enable high-titre LVV production using linear DNA vectors.
• Gain insights into overcoming bottlenecks in industrial-scale gene therapy manufacturing with innovative vector design

Download the full article below.